AzTrials
AzTrials

OsteomyelitisPCTNCT02308774

Osteomyelitis: Procalcitonin to Diagnose and Monitor Osteomyelitis (PCT)

An observational study of Osteomyelitis, run by University of Texas Southwestern Medical Center at 1 site in United States.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

We plan a cohort study of 40 diabetic patients admitted to Parkland hospital with a foot infection. We will enroll a representative cross section of subjects with diabetic foot infection. Patient will be consented and will receive therapy based on standard protocols. Read more about this study

Who is it for?
Ages 18 to 89 years
Conditions the study is for
Osteomyelitis
How many people
36 participants
Where
1 siteUnited States
Study dates
Aug 2014to Oct 2015
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 89 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Study population: Potential subjects will be identified from the investigator's inpatient and outpatient populations. This is not a treatment study, so subjects participating in other protocols will also be eligible to participate.

Who may be able to join

  • Diagnosis of diabetes mellitus
  • Age ≥ 21 years
  • Infectious Disease Society of America stage 3 infection

Who cannot join

  • History of previous bone infection in the study foot
  • Unable to provide informed consent
  • HIV, Hepatitis, osteomyelitis at other sites

Trial locations and contacts

1 site in 1 country.

United States1 site
  • UT Southwestern Medical Center

    Dallas, Texas, 75390-9132

Other trials in United States

About this study

Official title: Osteomyelitis: Procalcitonin to Diagnose and Monitor Osteomyelitis

We plan a cohort study of 40 diabetic patients admitted to Parkland hospital with a foot infection. We will enroll a representative cross section of subjects with diabetic foot infection. Patient will be consented and will receive therapy based on standard protocols. Currently patients with suspected osteomyelitis have bone biopsies to identify bacterial pathogens and verify MRI diagnosis. Repeat bone biopsies are performed at the end of therapy to verify that osteomyelitis has been successfully treated. Serum to measure procalcitonin will be obtained at baseline, week 3 and week 6.

Read the detailed description

Infection: will be defined as a patient with three of six clinical signs of infection (erythema, heat, edema, pain, loss of function, purulence) or leukocytosis. We will use the Infectious Diseases Society of America's Diabetic Foot Infection guidelines to stratify the severity of infection. This guideline stratifies infections into three categories (mild, moderate, and severe) based on practical clinical and laboratory findings. Our group has shown this system to be predictive of morbidity.

Osteomyelitis Diagnosis: We will evaluate suspected cases of osteomyelitis with bone biopsy for histology and culture and sensitivity. Bone biopsy to diagnose osteomyelitis is part of the standards of care established from the "diabetic foot infection guidelines" in our institution. We expect 1/4 of patients will have negative bone biopsy results. We will define a positive case of osteomyelitis as bone with positive bacterial cultures or histologic finding of acute osteomyelitis or chronic osteomyelitis. Acute osteomyelitis will be defined as the presence of acute inflammatory cells, congestion or thrombosis of medullary or periosteal small vessels, and necrotic bone. Chronic osteomyelitis will demonstrate areas of woven bone and fibrosis with large numbers of lymphocytes, histiocytes, and plasma cells.

Outcome Measures: Our primary endpoints will be resolution of osteomyelitis based on percutaneous bone biopsy six weeks after initiation of therapy. We will evaluate patients for six months for signs of recurrent osteomyelitis and other clinical outcomes (wounds, Charcot fracture, and infection). Clinical outcomes will include (1.) wound healing, (2.) limb salvage, (3.) hospitalizations for recurrent diabetic foot infection (4.) surgical procedures, and (5.) recurrent ulcers.

Confounding Variables: Most imaging studies of diabetic foot osteomyelitis do not assess potential confounding variables such as wound severity, diabetes severity, diabetes co-morbidities, and perfusion to the extremity. Outcomes such as wound healing and resolution of infection are clearly affected by current medical problems, social history, peripheral arterial disease, wound severity, and treatment factors such as type of antibiotics, off-loading, debridement and vascular surgery interventions. We will include the following variables in the study and in the analysis plan.

  1. Medical History: The diagnosis of diabetes will be based on American Diabetes Association criteria. We will evaluate glycated hemoglobin at baseline and quarterly per our standard of care. In addition, we will document: duration and type of diabetes, type of diabetes medication (insulin, oral, combination therapy, diet), previous history of foot ulcers, amputation (toe, foot), lower extremity bypass, lower extremity angioplasty, Coronary artery bypass surgery, cardiac angioplasty, arthritis, liver disease, osteoporosis, malignancy, and bone tumors. We will use the Kaplan co-morbidity index to record disease severity. We will use the New York Heart Association criteria to classify congestive heart failure, and the National Kidney Foundation Disease Outcomes Quality Initiative Clinical Practice Guidelines for chronic kidney disease to stage kidney disease. We will measure height and weight to determine body mass index (BMI). We will document all prescription and over-the-counter medications as well as the type, route and duration of antibiotic therapy.
  2. Social Factors: We will evaluate the following factors: marital status, years of education, type of work, tobacco history (pack years, current smoker, current use of chewing tobacco, previous smoker, no tobacco history), drug history (current, previous history, no drug history), and alcohol history.
  3. Vascular Assessment: We will assess perfusion of the macro-circulation with arterial Doppler studies and micro-circulation with Skin Perfusion Pressure measurements.
  4. Wound Assessment: We will use the University of Texas Diabetic Ulcer Classification to grade ulcer severity. We use acetate tracings, clinical measurements of length, width and depth and digital photos to measure wound area and volume before and after debridement. These technique has been shown to be highly reproducible. A wound will be considered "healed" when it is fully epithelialized with no drainage.
  5. Offloading and Debridement: For wounds on the weight-bearing surface of the foot, the most feasible offloading modality will be provided based on postural stability, wound location, and patient acceptance. Modalities available will be total contact cast, removable boot, healing sandal, and therapeutic shoes. Debridement will be performed as needed during the study.
Conditions
Osteomyelitis
Keywords
osteomyelitis, diabetic foot infection
Medical subject headings
Osteomyelitis

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. The primary endpoints will be changes in procalcitonin levels at Baseline, Week 3 and Week 6 correlated with resolution of osteomyelitis based on percutaneous bone biopsy six weeks after initiation of therapy.

    Serial measurements of procalcitonin at Baseline, Week 3 and Week 6.

    Measured: 6 weeks

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted4 Dec 2014 (estimated)
  2. Study startAug 2014
  3. Primary completionNov 2014
  4. Study completionOct 2015

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Prospective
Enrolment
36 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT02308774
Sponsor's protocol ID
022014-007
Acronym
PCT
Status last verified
Dec 2015
First submitted
7 Nov 2014
Last updated
14 Dec 2015
Results posted
No
Data monitoring committee
No

Questions about this trial

What is this clinical trial studying?

An observational study of Osteomyelitis, run by University of Texas Southwestern Medical Center at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 14 Dec 2015. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

The primary endpoints will be changes in procalcitonin levels at Baseline, Week 3 and Week 6 correlated with resolution of osteomyelitis based on percutaneous bone biopsy six weeks after initiation of therapy. (time frame: 6 weeks). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 14 Dec 2015.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in